Atavistik Bio
MA - CambridgeBiotechnology
Focus: Atavistik Bio is an early-stage oncology biotech leveraging a high-throughput screening platform to identify allosteric modulators of proteins. The company is pre-revenue with a single Phase 1 program and minimal public scale data.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Open Jobs
2
Should You Work at Atavistik Bio?
AI assessmentBest suited for early-stage technologists and scientists willing to accept pre-revenue risk in exchange for platform ownership; not appropriate for stability-focused candidates.
Why Work Here
- Access to novel platform technology (allosteric modulator screening) with potential to differentiate in competitive oncology space
- Early-stage role offers opportunity to shape scientific direction and build foundational capabilities before growth scaling
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ATV-1601
Advanced Solid TumorsOpen Jobs (2)
Help build intelligence for Atavistik Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.